Akèy › Kansè ovè › Ohio › Columbus
Etid klinik pou Kansè ovè nan Columbus, OH
39 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- ak 13 plis
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi lwen
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- The Mark H Zangmeister Center /ID# 275106, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Ap rekriteFaz 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Ap rekriteFaz 1/2
- The Ohio State University Wexner Medical Center, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Ap rekriteFaz 2
- Research Site, Columbus
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ap rekriteFaz 2
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard · 10 mi lwen
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- The Mark H Zangmeister Center, Columbus
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10 mi lwen
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 2
- The Mark H Zangmeister Cancer Center Ohio, Columbus
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard · 10 mi lwen
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Ohio Health Research Institute, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Ohio State University, Columbus
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ap rekriteFaz 2
- The Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi lwen
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Ap rekriteFaz 3
- Zangmeister Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ap rekriteFaz 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- OhioHealth Research Institute, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- The Ohio State University, Columbus
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Research Site, Columbus
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Ap rekriteFaz 2/3
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Ap rekriteFaz 1
- Ohio State University Wexner Medical Center, Columbus
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Ap rekriteFaz 1 bonè
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Ohio State University, Columbus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Ap rekriteFaz 3
- Site 0108, Columbus
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- ak 8 plis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- ak 8 plis
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Ap rekriteFaz 2/3
- Ohio State University Wexner Medical Center, Hilliard · 10 mi lwen
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ap rekriteFaz 2
- Ohio State University, Columbus
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Ap rekriteFaz 1/2
- Ohio State University, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Ap rekriteFaz 1
- Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Ap rekriteFaz 2
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Columbus
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Cleveland, OH30 etid
- Pittsburgh, PA30 etid
Lòt etid nan Columbus
- Kansè Poumon ki pa ti selil56 etid
- Kansè nan tete39 etid
- Kansè (tout kalite)38 etid
- Kansè poumon37 etid
- Leksemi mieloïd egi35 etid
- Lukemi lenfositè kwonik28 etid
- Kansè Metastatik27 etid
- Kansè Endomèt25 etid
- Kansè kolorektal24 etid
- Kansè pwostat24 etid
- Myelom Miltip24 etid
- Melanom21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.